RNA Editing Market Size was valued at USD 14.2 Billion in 2023. The RNA Editing Market industry is projected to grow from USD 15.0 Billion in 2024 to USD 22.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.00% during the forecast period (2024 - 2032). The rapid expansion of RNA Therapeutics and the expansion of genome editing applications are the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Increasing number of chronic diseases and disorders is likely to drive market CAGR for the RNA Editing Market over the forecast period. The high number of patients with infectious and chronic disorders drives up demand. The demand for remedies for infectious illnesses and cancer is expected to drive the global RNA-based therapeutics and vaccination market. Furthermore, according to WHO data, cancer is the world's second leading cause of mortality, accounting for 9.6 million deaths in 2018, or one out of every six. Cancers in men include lung, colorectal, stomach, prostate, and liver cancer, whereas cancers in women include breast, lung, cervical, colorectal, and thyroid. Furthermore, the patient pool is enormous, which is projected to be a growth driver for the global RNA-based treatments and vaccination market in the coming years.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has marked a watershed moment in the field of RNA editing, drastically altering our ability to accurately manipulate RNA sequences. This new method gives researchers and scientists unprecedented control over RNA molecules, allowing for highly precise targeted modifications. CRISPR-Cas13 and CRISPR-CasRx stand out from the arsenal of CRISPR-based technologies due to their high specificity and effectiveness in locating RNA targets for editing. The introduction of CRISPR-based RNA editing has not only altered basic research but has also accelerated advances in medicinal development, diagnostic applications, and functional genomics. Researchers can modify RNA sequences with unprecedented accuracy using CRISPR technology, offering new paths for treating a wide range of disorders at the genetic level.
As the field of RNA editing evolves, continuing research efforts are focused on refining and improving CRISPR-based RNA editing systems. The goal is to optimize delivery systems so that RNA molecules can be targeted efficiently and precisely within cells. Researchers are working to broaden the application of CRISPR-based RNA editing by enhancing its targeting capabilities and adaptability. These breakthroughs have enormous potential for the future of therapeutic treatments, notably in the areas of genetic disorders and infectious diseases. The increased precision and variety of CRISPR-based RNA editing technologies are expected to unleash novel therapeutic options, providing hope to patients suffering from previously incurable diseases.
The growing interest and investment in RNA editing research from both the public and private sectors is fueling innovation and technological improvement in the field. Funding agencies, academic institutions, biotechnology businesses, and pharmaceutical companies are all investing heavily in RNA editing research programmes, which include fundamental research, preclinical studies, and clinical trials. These investments are accelerating the development of innovative RNA editing technologies, the investigation of new therapeutic applications, and the transition of RNA editing-based medicines from the bench to the bedside. Collaborations and collaborations between academia and industry promote knowledge exchange, resource sharing, and technology transfer, hastening the pace of innovation in RNA editing technologies. Thus driving the RNA Editing Market revenue.
The RNA Editing Market segmentation, based on Type of RNA, includes Messenger RNA Modification, Transfer RNA Modification, and Ribosomal RNA Modification. The market for RNA editing technologies is now dominated by messenger RNA (mRNA) modification. mRNA plays an important role in gene expression by transporting genetic information from the DNA to the ribosomes, where it is translated into proteins. RNA modifications such as methylation and adenosine deamination control mRNA stability, splicing, localization, and translation efficiency, all of which influence cellular activities and gene expression patterns.
The RNA Editing Market is segmented based on Application into: Cancer, Genetic Disorders And Temporary Maladies. The cancer segment dominates the Global RNA Editing Technologies Market. Cancer's pervasiveness and complexity have fueled enormous research efforts to better understand the molecular mechanisms underlying oncogenesis and develop novel therapeutic options. RNA editing technologies have the potential to revolutionize cancer treatment by targeting aberrant RNA molecules linked to tumor growth, metastasis, and drug resistance.
The RNA Editing Market is segmented by Technique into Insertion/ Deletion And Deamination. The deamination category has emerged as the dominant force in the RNA editing market. This process involves the conversion of certain nucleotide bases within RNA molecules, often adenine (A) to inosine (I) or cytosine (C) to uridine (U), which is assisted by enzyme activity. The principal catalysts for deamination are adenosine deaminases acting on RNA (ADARs) and cytidine deaminases, such as APOBEC proteins. These events significantly impact RNA metabolism, gene expression regulation, and cellular functioning, affecting both physiological and pathological processes.
Figure 1: RNA Editing Market, By Technique, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. In 2023, North America was the dominating region. Several reasons contribute to North America's dominant position in this market category. North America has a strong research and development infrastructure, including leading academic institutions, biotechnology hubs, and pharmaceutical businesses pioneering RNA editing technologies. These universities are driving innovation and technology developments in RNA editing research, creating a vibrant ecosystem for collaboration and discovery.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: RNA EDITING MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe RNA Editing Market accounts for the second-largest market share. The region has a well-developed healthcare infrastructure and a trained workforce in molecular biology and genetics, which strengthens its position in the RNA editing market. Further, the Germany RNA Editing Market held the largest market share, and the UK RNA Editing Market was the fastest-growing market in the European region.
The Asia-Pacific RNA Editing Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to collaboration between local academic institutions, biotech businesses, and foreign partners on the rise in the region, promoting the development and deployment of RNA editing technology. Moreover, China RNA Editing Market held the largest market share, and the India RNA Editing Market was the fastest-growing market in the Asia-Pacific region.
RNA Editing Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the RNA Editing Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the RNA Editing industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global RNA Editing industry to benefit clients and increase the market sector. In recent years, the RNA Editing industry has offered some of the most significant advantages to medicine. Major players in the RNA Editing Market, including ProQR Therapeutics NV, Sirna Therapeutics, Inc., Shape Therapeutics, Inc. and others, are attempting to increase market demand by investing in research and development operations.
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical firm headquartered in Pasadena, California. Arrowhead's drugs in development use RNA interference (RNAi) methods of action. The company focuses on treatments for hepatitis B, liver illness caused by alpha 1-antitrypsin deficiency, and cardiovascular disease. The company has sixteen products in its pipeline at various levels of development. In October 2020, Arrowhead Pharmaceuticals entered into a partnership and licensing deal with Takeda Pharmaceutical. The partnership was aimed at developing ARO-AAT, a Phase 2 investigational RNA interference therapy for the treatment of alpha-1 antitrypsin-associated liver disease (AATLD).
Arbutus Biopharma Corporation, a publicly traded Canadian biopharmaceutical business (NASDAQ: ABUS), specializes in liposomal drug delivery and RNA interference and is developing treatments for hepatitis B infection. In Jun 2021, Arbutus Biopharma has inked a clinical collaboration agreement with Antios Therapeutics. The agreement was signed to evaluate a triple combination of Arbutus' proprietary GalNAc-delivered RNAi therapeutic, AB-729, Antios' proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus infection.
Key Companies in the RNA Editing Market include
RNA Editing Industry Developments
In June 2021, Arrowhead Pharmaceuticals signed a collaboration and licensing deal with Horizon Therapeutics. The collaboration aims to develop Arrowhead's ribonucleic acid interference (RNAi) therapy, ARO-XDH. This is an investigational short-interfering RNA therapy that targets the xanthine dehydrogenase.
In June 2020, Sarepta Therapeutics announced a collaboration with Codiak Biosciences, a firm pioneering the development of modified exosomes. The collaboration centered on designing and manufacturing engineered exosome therapies to provide gene editing, gene therapy, and RNA technologies for neuromuscular illnesses.
In April 2020, Alnylam Pharmaceuticals partnered with Blackstone, who offered up to $2 billion to promote the development of new RNA interference treatments.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 14.2 Billion |
| Market Size 2024 | USD 15.0 Billion |
| Market Size 2032 | USD 22.6 Billion |
| Compound Annual Growth Rate (CAGR) | 6.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type of RNA, Application, Technique and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â ProQR Therapeutics NV, Sirna Therapeutics, Inc., Shape Therapeutics, Inc., Korro Bio, Inc., Beam Therapeutics, Inc., QIAGEN N.V., UniQure NV (UniQure), LAVA Therapeutics N.V., argenx SE and Arrowhead Pharmaceuticals, Inc. |
| Key Market Opportunities | ·      Growing investments in RNS editing research |
| Key Market Dynamics | ·      Expansion of genome editing applications |
Frequently Asked Questions (FAQ) :
The RNA Editing Market size was valued at USD 14.2 Billion in 2023.
The global market is projected to grow at a CAGR of 6.00% from 2024 to 2032.
North America had the largest share of the global market.
The key players in the market are ProQR Therapeutics NV, Sirna Therapeutics, Inc., Shape Therapeutics, Inc. and others.
The Deamination category dominated the market in 2023.
The Cancer category had the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
